BitMine, the largest single buyer of Ether, is set to stop its weekly purchases within six to seven weeks after reaching 4.9% of the circulating Ether supply, just shy of its 5% cap. This halt comes as Ether ETFs experience significant outflows, totaling over $500 million in five days, adding selling pressure to the market. Additionally, the upcoming Ethereum network upgrade, Glamsterdam, lacks a fixed mainnet activation date, reducing potential bullish catalysts. Investors should consider holding periods, buying routes, and staking options carefully as market dynamics shift with BitMine's exit and ongoing ETF withdrawals.
The story about BitMine's Ether buying cap is presented here with Pluang's market data for context. As of Oct 08, 2026 19:02 WIB, 23 of 50 major cryptocurrencies rose while 26 fell. EOS gained 8.13% to Rp12.649, ATOM increased 7.41% to Rp32.222 with a typical hold time of 60 days, and ONE dropped 5.50% to Rp37 with a typical hold time of 152 days.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
